Compare Stocks: OSIR, NAMS, CDNA, and VRDN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$50.26	$42.84	$13.23 ▼ $53.67	$2.60B	2.43	1.10 million shs	662,907 shs
NAMS NewAmsterdam Pharma	$22.80	$28.60	$21.23 ▼ $42.21	$2.73B	0.09	1.23 million shs	1.60 million shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
VRDN Viridian Therapeutics	$21.24	$21.47	$13.18 ▼ $34.29	$2.41B	0.97	1.16 million shs	943,151 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	-1.22%	+10.90%	+108.72%	+271.47%
NAMS NewAmsterdam Pharma	0.00%	-10.24%	-15.49%	-25.49%	-5.75%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VRDN Viridian Therapeutics	0.00%	-7.33%	-3.80%	+30.31%	+12.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$50.26	$42.84	$13.23 ▼ $53.67	$2.60B	2.43	1.10 million shs	662,907 shs
NAMS NewAmsterdam Pharma	$22.80	$28.60	$21.23 ▼ $42.21	$2.73B	0.09	1.23 million shs	1.60 million shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
VRDN Viridian Therapeutics	$21.24	$21.47	$13.18 ▼ $34.29	$2.41B	0.97	1.16 million shs	943,151 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	-1.22%	+10.90%	+108.72%	+271.47%
NAMS NewAmsterdam Pharma	0.00%	-10.24%	-15.49%	-25.49%	-5.75%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VRDN Viridian Therapeutics	0.00%	-7.33%	-3.80%	+30.31%	+12.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.63	Moderate Buy	$51.20	1.87% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.73	118.10% Upside
OSIR Osiris Therapeutics	0.00	N/A	N/A	N/A
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.54	81.44% Upside

Current Analyst Ratings Breakdown

Latest OSIR, NAMS, CDNA, and VRDN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	NAMS NewAmsterdam Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$52.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
8/6/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2026	CDNA CareDx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $60.00
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
8/3/2026	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$64.00
7/31/2026	CDNA CareDx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$46.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	6.85	N/A	N/A	$5.89 per share	8.53
NAMS NewAmsterdam Pharma	$22.50M	121.13	N/A	N/A	$5.97 per share	3.82
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	$70.85M	33.96	N/A	N/A	$6.18 per share	3.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	24.28	79.78	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest OSIR, NAMS, CDNA, and VRDN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
OSIR Osiris Therapeutics	N/A	N/A	N/A
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
NAMS NewAmsterdam Pharma	89.89%
OSIR Osiris Therapeutics	0.28%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
NAMS NewAmsterdam Pharma	12.74%
OSIR Osiris Therapeutics	43.40%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
OSIR Osiris Therapeutics	342	34.53 million	N/A	Not Optionable
VRDN Viridian Therapeutics	252	113.29 million	110.57 million	Optionable

OSIR, NAMS, CDNA, and VRDN Headlines

Recent News About These Companies

Squarepoint Ops LLC Purchases 133,046 Shares of Viridian Therapeutics, Inc. $VRDN

September 13 at 4:15 AM | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 10, 2026 | americanbankingnews.com

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8, 2026 | globenewswire.com

Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

September 8, 2026 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5, 2026 | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3, 2026 | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2, 2026 | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31, 2026 | marketbeat.com

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25, 2026 | marketbeat.com

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSIR, NAMS, CDNA, and VRDN Company Descriptions

CareDx NASDAQ:CDNA

$50.26 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$50.33 +0.07 (+0.14%)

As of 05:16 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

NewAmsterdam Pharma NASDAQ:NAMS

$22.80 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$22.80 0.00 (-0.02%)

As of 09/11/2026 07:30 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)

As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Viridian Therapeutics NASDAQ:VRDN

$21.24 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$21.11 -0.13 (-0.60%)

As of 04:28 AM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSIR, NAMS, CDNA, and VRDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSIR, NAMS, CDNA, and VRDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSIR, NAMS, CDNA, and VRDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSIR, NAMS, CDNA, and VRDN Company Descriptions

CareDx NASDAQ:CDNA

NewAmsterdam Pharma NASDAQ:NAMS

Osiris Therapeutics OTCMKTS:OSIR

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSIR, NAMS, CDNA, and VRDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSIR, NAMS, CDNA, and VRDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSIR, NAMS, CDNA, and VRDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSIR, NAMS, CDNA, and VRDN Company Descriptions

CareDx NASDAQ:CDNA

NewAmsterdam Pharma NASDAQ:NAMS

Osiris Therapeutics OTCMKTS:OSIR

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools